TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement of residents
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: GERD Symptom Elimination or Clinically Significant Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Elimination of Daily Troublesome Regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reported or noted adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Communicative patient's pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non communicative patient's pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation/agitation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance at the metabolic anaerobe barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in central BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in ambulatory BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-Year Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis of Acute Heart Failure (AHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Cytokine (IL-4, IL-10, IFN- γ, TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Dose Limiting Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Maternal Anxiety (GAD-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Maternal Anxiety (Pregnancy Specific Anxiety Score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal Anxiety (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lab test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in modified EASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sinonasal Outcome Test (SNOT 20)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nasal Endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT Scan Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Perfusion by PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Perfusion by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IgG total levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgG subclass 4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: atopy patch test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient satisfaction-comfort and convenience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: scar improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in IRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar bone filling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensor Dot usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensor Dot data quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in systemic levels of DHEA (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in systemic levels of TRIAC (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in systemic levels of DHEA-S (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Treatment or Failure Defined as Vitrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety (Injected-related, Ocular Drug-related and Systemic Drug-related)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient surgical Experience Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NSQIP Patient Reported Surgical Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference of iodine uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Morphine equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection and quantification of HPV DNA types 16 and 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Oral status of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Post-ureteroscopy Stent-induced Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical state improvement evaluated by CGI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of responders defined with CGI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fahn-Tolosa-Marin Tremor Rating Scale (TRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Remission of pouchitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late Asthmatic Response (AUC in FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early Asthmatic Response (AUC in FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Late Asthmatic Response (Maximum Fall in FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early Asthmatic Response (Maximum Fall in FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ratio of final infarct size at 3 months over area at risk at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hamilton Depression Rating Scale (21-item version)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Incidence of Rash
Endpoint domain: Adverse events/effects
Primary endpoint: Time Duration From Onset of Rash Until Resolution
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Incidence of Grade 3 Rash
Endpoint domain: Adverse events/effects
Primary endpoint: Peri-stomal skin condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase of salivary cortisol titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Duration of first stage of labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: CT Thorax parameters reflecting emphysema airway remodelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Penis circumference change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance at steady state (CLss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective behavioral strategy use
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Overall Weekly Alcohol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved iron status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in Left Ventricular Mass Indexed (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with ISTH major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with symptomatic recurrent VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Injection Site Reactions Following the First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Systemic Reactions Following the First Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Hematology, Serum Chemistry, and Urinalysis Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Beginning of Relief of Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in COVID-19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events, serious adverse events and dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in composite of laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in electrocardiogram values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in composite of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of PK parameters as a measure of RP2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Metaphase II Cells (MII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in IBS-SSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ultrasound vascularity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage change of HDL2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Etanercept seroreactivity response
Endpoint domain: Adverse events/effects
Primary endpoint: Post void residual urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in AUCs for EPISPOT and Cellsearch Techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly average daily pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Oxygen Desaturation Index (ODI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Ghrelin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Peptide YY AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in GLP-1 AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline Vaginal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gestation rate
Endpoint domain: Mortality/survival
Primary endpoint: Postacne scarring severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fitness center attendance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change WOMAC Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC Function Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic binary restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of FMAU-PET score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Actuarial survival at one year after onset of graft versus host disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of accurate high-grade squamous intraepithelial lesion (HSIL) diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection rates of vascular patterns of high-grade cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of concordance between vascular patterns and biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of Participants With Urticaria Control Test Score ≥ 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visceral adipose tissue levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Simulator driving errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 52-Week Point-Prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24h melatonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in QT interval corrected by Fridericia method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eating disorder behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of improvement in UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Quality of Life Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline on 11-item ADAS-Cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Minimal important difference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of a multi-analyte blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Body Weight (Kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index (kg/m^2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure (mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Alive and Free of Respiratory Failure
Endpoint domain: Mortality/survival
Primary endpoint: Bronchodilator effect (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inhaled Antibiotic collection percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hemoglobin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to Biochemical Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Met Biochemical Failure Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Stable Disease or Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of Stable Disease or Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of selected markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48
Endpoint domain: Adverse events/effects
Primary endpoint: photoallergic potential
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and magnitude of nocturnal hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acquisition of HIV-1
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis of invasive colorectal adenocarcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Diabetes Self-Care Activities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rate of completion of all adjuvant immunotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of Dulaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Best Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal aortic measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Popliteal artery measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HPV recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IFN-gamma induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Level of Diindolylmethane in Prostate Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 and 4 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: T807-PET measures of PHF-tau
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: T807-PET measures in healthy aging, preclinical AD, and early symptomatic AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: T807-PET measures of cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Urine protein/creatinine ratio (UP/C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom documentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: febrile episode
Endpoint domain: Adverse events/effects
Primary endpoint: 5-time chair stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Who Showed no Worsening
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total time involved in preoperative anesthesia consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SO manometric data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Chromium and Cobalt Ion Levels Above 7ug/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Articular Noise Produced During Level Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Articular Noise Produced During Level Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of Articular Noise Produced During Level Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of diabetes education on new onset diabetes management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thiamine status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of response/control of cerebral metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Successful Thyroid Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Symptomatic Intracranial Hemorrhage (SICH)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Completing the Protocol-assigned Stimulation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Assessing the Speed of Stimulation Implementation From Randomization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hamilton Anxiety Rating (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety in patients with mild to moderate psoriasis
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of treatment-limiting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMTs) for Anti-HPV 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Seroconverted for HPV Type 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Achieved Acceptable Levels of Titers to Diphtheria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Present Pain Intensity (PPI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of Change in Blood Lymphocyte NF-kB Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Mobility Test Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes